Satellos Bioscience Inc. (MSCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has a cash flow conversion efficiency ratio of -0.266x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-7.38 Million ≈ $-5.34 Million USD) by net assets (CA$27.73 Million ≈ $20.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MSCL net asset quality score to measure how much of total assets are equity-financed.
Satellos Bioscience Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Satellos Bioscience Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore investment intensity of Satellos Bioscience Inc. to see how much of total assets are deployed in long-term investments.
Satellos Bioscience Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Satellos Bioscience Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peninsula Group Ltd
TA:PEN
|
-0.033x |
|
Yatsen Holding
NYSE:YSG
|
-0.033x |
|
Red Hill Minerals Ltd
AU:RHI
|
0.084x |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
N/A |
|
COG Financial Services Ltd
AU:COG
|
0.198x |
|
Meridian Bank
NASDAQ:MRBK
|
-0.030x |
|
CSG Holding Co Ltd
SHE:200012
|
0.023x |
|
Decora SA
WAR:DCR
|
0.048x |
Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see MSCL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$27.73 Million ≈ $20.06 Million |
CA$-24.01 Million ≈ $-17.37 Million |
-0.866x | -135.23% |
| 2024-12-31 | CA$67.86 Million ≈ $49.09 Million |
CA$-24.98 Million ≈ $-18.07 Million |
-0.368x | -3.83% |
| 2023-12-31 | CA$40.67 Million ≈ $29.42 Million |
CA$-14.42 Million ≈ $-10.43 Million |
-0.354x | +79.35% |
| 2022-12-31 | CA$3.37 Million ≈ $2.44 Million |
CA$-5.78 Million ≈ $-4.18 Million |
-1.717x | -257.45% |
| 2021-12-31 | CA$10.48 Million ≈ $7.58 Million |
CA$-5.03 Million ≈ $-3.64 Million |
-0.480x | -105.32% |
| 2020-12-31 | CA$-183.84K ≈ $-132.98K |
CA$-1.66 Million ≈ $-1.20 Million |
9.030x | +291.71% |
| 2019-12-31 | CA$408.57K ≈ $295.56K |
CA$-1.92 Million ≈ $-1.39 Million |
-4.710x | -- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more